Leveragen Inc., a Boston-based biotechnology company specializing in next-generation genetic models for antibody discovery, ...

With National Nutrition Month in full swing, the excitement continues with Eggland's Best and Club Pilates! The "Eggland's Best for EveryBODY" Sweepstakes is still underway, giving fans the chance to ...

Campaigns, a public health initiative that promotes sustainable behavior change by dedicating every Monday to health, announced its next chapter today. The Johns Hopkins Center for a Livable Future ...

DelveInsight's "CABLIVI Market Size, Forecast, and Market Insight Report" highlights the details around CABLIVI, a von ...

Developed by Sanofi, CABLIVI is the first FDA-approved nanobody therapy for this condition. Increasing awareness, improved diagnostic rates, and rising demand for targeted therapies in hematology ...

Seventy-one University of Kentucky students will present their research at the National Conference on Undergraduate Research ...

It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis.

The new drug candidate for FSHD will combine an RNA molecule from miRecule targeting double homeobox 4 (DUX4) – a protein that is mutated in FSHD – with a nanobody developed by Sanofi that ...

AstraZeneca’s EsoBiotec acquisition is the latest in a series of deals struck by the pharma giant to secure a place in the next wave of cell therapies for cancer and immune-mediated diseases.

AstraZeneca has entered into a definitive agreement to acquire EsoBiotec, a biotechnology company pioneering in vivo cell ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...